Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCTs041250103) titled 'RCT of Anamorelin to evaluate RDI of adjuvant chemotherapy in gastric cancer patients' on Sept. 26.
Study Type: Interventional
Study Design:
randomized controlled trial, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose
Primary Sponsor: Tanaka Chie
Condition:
Gastric Cancer
Gastric Cancer, Anamorelin
Stomach Neoplasms
Intervention:
Registration and randomization: Performed within 42 days after gastrectomy.
Intervention: Oral administration of anamorelin hydrochloride at 100 mg/day in the morning, for a total duration of 12 weeks....
Recruitment...